Stockscreener 앱 받기
49.41
2.26%
0.8987
전일 마감가:
$48.51
열려 있는:
$48.86
하루 거래량:
369.60K
Relative Volume:
0.64
시가총액:
$2.04B
수익:
$17.39M
순이익/손실:
$-135.89M
주가수익비율:
-10.65
EPS:
-4.64
순현금흐름:
$-123.00M
1주 성능:
+0.99%
1개월 성능:
-0.73%
6개월 성능:
+30.54%
1년 성능:
+53.62%
1일 변동 폭
$48.35
$49.77
1주일 범위
$46.94
$50.30
52주 변동 폭
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
TARS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
49.45 | 2.04B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.84 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.37 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.96 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.63 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.95 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus Pharmaceuticals (TARS) Highlights Global Impact of Demodex Blepharitis at ASCRS 2025 | TARS Stock News - GuruFocus
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting - GlobeNewswire
Learn to Evaluate (TARS) using the Charts - news.stocktradersdaily.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by JPMorgan Chase & Co. - Defense World
Midday Stock Roundup: Healthcare, medtech stocks tumble - Orange County Business Journal
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Vanguard Group Inc. - Defense World
Papulopustular Rosacea Market Expected to Experience Major Growth by 2034, According to DelveInsight | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer - Barchart.com
KLP Kapitalforvaltning AS Invests $299,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Sei Investments Co. Purchases 12,689 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
HighTower Advisors LLC Invests $207,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Raymond James Financial Inc. Makes New $1.11 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(TARS) Trading Report - news.stocktradersdaily.com
With Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) It Looks Like You'll Get What You Pay For - simplywall.st
Teacher Retirement System of Texas Has $438,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Fastest-Growing Public Cos. Ride Healthcare Boom - Orange County Business Journal
Tarsus Pharmaceuticals CEO sells $300,000 in stock By Investing.com - Investing.com Canada
Swiss National Bank Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals CEO sells $300,000 in stock - Investing.com India
4,031 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Victory Capital Management Inc. - Defense World
Where are the Opportunities in (TARS) - news.stocktradersdaily.com
Tarsus Pharmaceuticals CFO Jeffrey Farrow sells $178,306 in stock By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CEO Bobak Azamian sells $1.16 million in stock By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals chief commercial officer sells $505,856 in stock By Investing.com - Investing.com India
Tarsus Pharmaceuticals COO Neervannan Seshadri sells $363,141 in stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals’ general counsel sells shares worth $463,765 By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CFO Jeffrey Farrow sells $178,306 in stock - Investing.com
Tarsus Pharmaceuticals’ general counsel sells $463,765 in stock - Investing.com India
Tarsus Pharmaceuticals CEO Bobak Azamian sells $1.16 million in stock - Investing.com
Tarsus Pharmaceuticals’ general counsel sells shares worth $463,765 - Investing.com
Tarsus Pharmaceuticals chief commercial officer sells $505,856 in stock - Investing.com
Tarsus Pharmaceuticals’ HR chief sells shares worth $321,323 - Investing.com
Tarsus Pharmaceuticals COO Neervannan Seshadri sells $363,141 in stock - Investing.com
Tarsus Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Tarsus Pharmaceuticals completes $134.8M stock offering By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals completes $134.8M stock offering - Investing.com India
Tarsus prices $125M stock offering - MSN
Tarsus Pharma dips after upsized $125 mln stock offering - TradingView
Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering -March 13, 2025 at 03:44 am EDT - Marketscreener.com
Tarsus Pharmaceuticals launches $100 million stock offering - Investing.com Australia
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewswire
Tarsus Secures Massive $125M Capital Raise as Investors Rush Into Upsized Offering - StockTitan
Tarsus Announces Pricing Of Upsized $125 Million Public Offering -March 12, 2025 at 09:50 pm EDT - Marketscreener.com
Tarsus Pharmaceuticals dips on planned $100 million equity raise - TradingView
Tarsus Pharmaceuticals launches $100 million stock offering By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
2.22%
자본화:
|
볼륨(24시간):